168 related articles for article (PubMed ID: 36246006)
1. Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma.
Abramson DH; Mandelker D; Francis JH; Dunkel IJ; Brannon AR; Benayed R; Berger MF; Arcila ME; Ladanyi M; Friedman DN; Jayakumaran G; Diosdado MS; Robbins MA; Haggag-Lindgren D; Shukla N; Walsh M; Kothari P; Tsui DWY
Ophthalmol Sci; 2021 Mar; 1(1):100015. PubMed ID: 36246006
[TBL] [Abstract][Full Text] [Related]
2.
Francis JH; Gobin YP; Brannon AR; Swartzwelder CE; Berger MF; Mandelker DL; Walsh MF; Dunkel IJ; Abramson DH
Ophthalmol Sci; 2021 Sep; 1(3):100042. PubMed ID: 36247821
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience.
Kothari P; Marass F; Yang JL; Stewart CM; Stephens D; Patel J; Hasan M; Jing X; Meng F; Enriquez J; Huberman K; Viale A; Francis JH; Berger MF; Shukla N; Abramson DH; Dunkel IJ; Tsui DWY
Cancer Med; 2020 Sep; 9(17):6093-6101. PubMed ID: 32633890
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis.
Jiménez I; Frouin É; Chicard M; Dehainault C; Le Gall J; Benoist C; Gauthier A; Lapouble E; Houdayer C; Radvanyi F; Bernard V; Brisse HJ; Gauthier-Villars M; Stoppa-Lyonnet D; Baulande S; Cassoux N; Lumbroso L; Matet A; Aerts I; Renault V; Doz F; Golmard L; Delattre O; Schleiermacher G
Eur J Cancer; 2021 Sep; 154():277-287. PubMed ID: 34298378
[TBL] [Abstract][Full Text] [Related]
5. Cell Free DNA (cfDNA) in the Blood of Retinoblastoma Patients The Robert M. Ellsworth Lecture.
Abramson DH
Ophthalmic Genet; 2022 Dec; 43(6):731-735. PubMed ID: 35382685
[TBL] [Abstract][Full Text] [Related]
6. Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study.
Abramson DH; Mandelker DL; Brannon AR; Dunkel IJ; Benayed R; Berger MF; Arcila ME; Ladanyi M; Friedman DN; Jayakumaran G; Diosdado MS; Robbins MA; Haggag-Lindgren D; Shukla N; Walsh MF; Kothari P; Tsui DWY; Francis JH
PLoS One; 2023; 18(2):e0271505. PubMed ID: 36735656
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy in Retinoblastoma: A review.
Ghose N; Kaliki S
Semin Ophthalmol; 2022; 37(7-8):813-819. PubMed ID: 35604935
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Posttreatment Measurements and Clinical Correlates in Retinoblastoma.
Abramson DH; Robbins MA; Gobin YP; Dunkel IJ; Francis JH
JAMA Ophthalmol; 2024 Mar; 142(3):257-261. PubMed ID: 38300595
[TBL] [Abstract][Full Text] [Related]
11. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
14. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma.
Berry JL; Xu L; Murphree AL; Krishnan S; Stachelek K; Zolfaghari E; McGovern K; Lee TC; Carlsson A; Kuhn P; Kim JW; Cobrinik D; Hicks J
JAMA Ophthalmol; 2017 Nov; 135(11):1221-1230. PubMed ID: 29049475
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
16. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.
Zhou C; Yuan Z; Ma W; Qi L; Mahavongtrakul A; Li Y; Li H; Gong J; Fan RR; Li J; Molmen M; Clark TA; Pavlick D; Frampton GM; Forcier B; Moore EH; Shelton DK; Cooke M; Ali SM; Miller VA; Gregg JP; Stephens PJ; Li T
J Hematol Oncol; 2018 Nov; 11(1):129. PubMed ID: 30400986
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
19. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
[TBL] [Abstract][Full Text] [Related]
20. Diffuse Infiltrating Retinoblastoma with Anterior Chamber Involvement: Conservative Management and Identification of
Cassoux N; Malaise D; Lumbroso-Le-Rouic L; Le Gall J; Golmard L; Cardoen L; Freneaux P; Bouchoucha Y; Aerts I; Doz F; Matet A
Ocul Oncol Pathol; 2023 Sep; 9(3-4):96-100. PubMed ID: 37900191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
